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Salam Pradeep Singh* and Bolin Kumar KonwarAbstract
Nitric oxide synthases (NOS) catalyze to produce nitric oxide (NO) from L-arginine. The isoform of NOS i.e. inducible
nitric oxide synthases (iNOS) expression is observed in various human malignant tumors such as breast, lung,
prostate and bladder, colorectal cancer, and malignant melanoma. Also an increased level of iNOS expression and
activity has been found in the tumor cells of gynecological malignancies, stroma of breast cancer and tumor cells
of head and neck cancer. Because of its importance in causing tumors and cancer, iNOS enzyme has become a
new target in finding novel inhibitors as anti cancer agents. The present work focuses on the molecular docking
analysis of quercetin and its analogues against iNOS enzyme. Earlier there are reports of quercetin inhibiting iNOS
enzyme in certain experiments as anti cancer agent. But the clinical use of quercetin is limited by its low oral
bioavailability and therefore needed its molecular modification to improve its pharmacological properties. In the
present study ten analogues of quercetin were found to be docked at the active site cavity with favorable
ligand-protein molecular interaction and interestingly from the ADME-Toxicity analysis these analogues have
enhanced pharmacological properties than quercetin.
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Nitric oxide synthases (NOS) (EC 1.14.13.39) are a family
of enzymes that catalyze producing nitric oxide (NO) from
L-arginine. It is an important cellular signaling molecule,
having a role in various cellular processes. The free radical
(NO) is an important effector molecule in the nervous,
immune and cardio vascular systems (Garthwaite and
Boulton 1995; MacMicking et al. 1997; Michel and Feron,
1997). Mammals contain three isoforms of NOS that pro-
duce NO and citrulline by catalyzing NADPH and O2
dependent oxidation of L-arginine (Griffith and Stuehr
1995; Marletta et al. 1997). Two isoforms of NOS are
expressed in cells such as neurons (nNOS) and endothe-
lium (eNOS) which are activated by Ca+2 dependent cal-
modulin (CaM) binding and the third inducible isoform
(iNOS) is induced by cytokines which binds CaM inde-
pendently (Ghosh et al., 1999). The iNOS isoform is a
homodimer (Michal 1999) and the iNOS gene is located* Correspondence: salampradeep@gmail.com
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reproduction in any medium, provided the origon chromosome 17 (Xu et al. 1994). iNOS exerts its func-
tions independent of Ca+2 while calmodulin remains non-
covalently bound to the iNOS complex and forms an
essential subunit of the isoform (Knowles and Moncada
1994, Cho et al. 1992). Regulating NO production via
iNOS necessarily occurs during transcription and transla-
tion, for once active, iNOS synthesizes large amounts of
NO until substrate depletion (Hickey et al. 2001). The role
of NO affects the expression and activity of oncogenes,
which are vital to the cell cycle and apoptosis (Forrester
et al. 1996; Messmer et al. 1994; Sandau et al. 1997). For-
rester et al. observed an up regulation of the tumor sup-
pressor gene p53 after the exposure of cells to NO donors
which might be a reaction due to NO mediated DNA
damage (Forrester et al. 1996). Also, the p53 gene is an
important inhibitor for iNOS expression as it regulates
NO production by a negative feedback loop mechanism.
The non-mutant p53 protein (wild-type form) binds to a
site on the iNOS gene, preventing its transcription
(Brennan and Moncada 2002). Thus, suggesting the wild-
type p53 is vital for the control of NO mediatedhis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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with mutant p53 animal tumors have found out there is
an increase in NOS activity in such cancers which grew
faster with greater angiogenic potential. Thus, promoting
cancer progression by providing a selective growth advan-
tage to tumor cells (Ambs et al. 1998a). NO could also
be shown to activate p53 resulting in anti-carcinogenic
effects, mutagenic and increase cancer risk (Goodman
et al. 2004, Rao 2004). The multifactorial process involved
in carcinogenesis requires mutations in somatic cells and
subsequent alterations of morphology and growth pattern,
eventually resulting in transformation, local invasion, and
metastasis (Lirk et al. 2002). The expression of iNOS can
be observed in a various human malignant tumors such as
breast (Vakkala et al. 2000), lung (Marrogi et al. 2000),
prostate (Aaltoma et al. 2001; Aaltomaa et al. 2000; Uotila
et al., 2001) and bladder (Swana et al. 1999; Hayashi et al.
2001), colorectal cancer (Kojima et al. 1999), and malig-
nant melanoma (Massi et al. 2001). However, there are
many conflicting reports that increased levels of iNOS are
not a ubiquitous finding in human cancer and its expres-
sion depends on the histological type or grade of the
tumor and the tumor stage (Crowell et al. 2003; Kinaci
et al. 2012). Various studies have also found out the
expression and the activity of iNOS in human cancer
(Weiming et al. 2002; James et al. 2003). An increased
level of iNOS expression and activity has been found in
the tumor cells of gynecological malignancies, (Thomsen
et al., 1994) in the stroma of breast cancer, (Thomsen
et al. 1995) and in the tumor cells of head and neck cancer
(Gallo et al. 1998; Franchi et al. 2002). Several studies have
reported an increase of iNOS expression in tumor tissue
when compared with normal mucosa (Ambs et al. 1998b;Table 1 Docking score of the top docking hits and quercetin
SN Ligand MolDocka Rerankb Intera
1 5281604 −129.14 −104.75 −148.2
2 5315126 −122.90 −102.63 −146.1
3 9818879 −133.99 −95.04 −150.4
4 5481966 −122.87 −93.67 −141.7
5 5282154 −116.71 −93.58 −135.9
6 13964550 −113.94 −93.40 −130.6
7 5281691 −124.63 −92.63 −144.5
8 11834044 −116.92 −91.50 −140.6
9 6477685 −130.50 −91.09 −144.1
10 Quercetin −77.29 −65.79 −97.17
a - Moldock score is derived from the PLP scoring functions with a new hydrogen b
b - The rerank score is a linear combination of E-inter (steric, Van der Waals, hydrog
(torsion, sp2-sp2, hydrogen bonding, Van der Waals, electrostatic) of the ligand wei
c - The total interaction energy between the pose and the protein (kJ mol−1).
d - The internal energy of the pose.
e - Hydrogen bonding energy (kJ mol−1).
f - Ligand Efficiency 1: MolDock Score divided by Heavy Atoms count.
g - Ligand Efficiency 3: Rerank Score divided by Heavy Atoms count.Ambs et al. 1999; Ropponen et al. 2000; Yagihashi et al.
2000; Kojima et al. 1999; Hao et al. 2001).
The present work aims on molecular docking analysis of
iNOS enzyme against a class of flavonoid (quercetin and
its analogues) which is present in fruits, vegetables, leaves
and grains and is reported to have effective anti-cancer
property. Scientists have long considered quercetin and
flavonoids present in fruits, vegetables, leaves and grains
important in cancer prevention. There are also reports of
lower risk of cancer in people who eat more fruits and
vegetables. (Verschoyle et al. 2007; Rietjens et al. 2005; van
der Woude et al. 2005; Chen et al. 2001). Interestingly,
quercetin inhibiting against iNOS as anti cancer agents
has been reported by García-Mediavilla et al. and Raso
et al. (García-Mediavilla et al. 2007; Raso et al. 2001). But
the clinical use of quercetin is limited by its low oral bio-
availability (Peng et al. 2008) and therefore compels its
molecular modification to enhance its pharmacological
properties. In the present study the best docking hit analo-
gues were undergo ADME–Toxicity prediction (absorp-
tion, distribution, metabolism, and toxicity) to evaluate its
pharmacological properties to be an orally active com-
pound. Here in the present work, we are reporting for the
first time the analogues of quercetin as iNOS inhibitors
with enhanced pharmacological properties.
Results and discussion
Molecular docking analysis
Quercetin (3,3’,4’,5,7-pentahydroxylflavone) is a plant
derived flavonoid which is present in the plant kingdom
as a secondary metabolite. It is the most well defined
group of polyphenolic compounds (Murakami et al.,
2008). The flavonoids contain a basic skeleton ofctionc Internald HBonde LE1f LE3g
7 19.14 −11.81 −5.61 −4.55
1 23.21 −15.38 −4.55 −3.80
4 16.46 −9.33 −5.58 −3.96
3 18.86 −2.43 −4.55 −3.47
8 19.27 −14.02 −4.86 −3.90
2 16.68 −4.56 −5.18 −4.25
7 19.94 −7.95 −5.42 −4.03
7 23.75 −13.46 −5.08 −3.98
3 13.63 −4.18 −5.67 −3.96
19.88 −8.42 −3.51 −2.99
onding term and new charge schemes. (Thomsen and Christensen 2006).
en bonding, electrostatic) between the ligand and the protein, and E-intra.
ghted by pre-defined coefficients. (Thomsen and Christensen 2006).
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http://www.springerplus.com/content/1/1/69diphenylpropane (C6–C3–C6). Quercetin is commonly
found as O-glycosides with one of its hydroxyl group is
substituted by sugars of various type. In this report, we
have highlighted molecular docking studies on the inhib-
ition of iNOS by quercetin and its analogues. Molecular
docking was carried out using Molegro Virtual Docker,
MVD 5.0 (Molegro 2011). The top poses were found to
be lying deep into the binding cavity of iNOS enzyme
showing all the major interaction and a favourable in-Table 2 Molecular interaction analysis of the top three dockin




































HEM - Protoporphyrin IX containing Fe.teraction energy than quercetin ranging from −130.62 to
−150.44 compared with −97.17of quercetin. The top
docking hits were bound within the active site cavity
consisting of the protoporphyrin IX containing Fe
(HEM) revealing molecular interaction with the active
site residues and HEM. The analogues docked at the
binding cavity have a rerank score ranging from −104.75
(CID5281604) to −65.79 (quercetin) as shown in Table 1.









































Figure 1 (A) Predicted bonded interactions (green dashed lines) between CID5281604 (green) and Trp346, Tyr347, Val352, Phe369,
Tyr373, Asp382 residues and HEM molecule of iNOS (B) binding mode of CID5281604 (green) to iNOS active site region (C) Binding
mode representing the ligand based on atom type and the protein based on amino acid residue type colouring.
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http://www.springerplus.com/content/1/1/69(steric, Van der Waals, hydrogen bonding, electrostatic)
between the ligand and the protein, and E-intra (torsion,
sp2-sp2, hydrogen bonding, Van der Waals, electrostatic)
of the ligand weighted by pre-defined coefficients
(Thomsen and Christensen 2006). Also, the top three
docking hits have a MolDock score of −129.14 for
CID5281604, −122.90 for CID5315126, −133.99 for
CID9818879 and −77.29 for quercetin.
The MolDock scoring function (MolDock Score) is
derived from the PLP scoring functions originally proposed
by Gehlhaar et al. (Gehlhaar et al. 1995, Gehlhaar et al.
1998) and later extended by Yang et al. (Yang and Chen
2004). The MolDock scoring function further improves
these scoring functions with a new hydrogen bonding term
and new charge schemes. The docking scoring function,
Escore, is defined by the following energy terms:
EScore ¼ Einter þ E intra
Where,
Einter is the ligand-protein interaction energy
Eintra is the internal energy of the ligandFigure 2 (A) Predicted bonded interactions (green dashed lines) betw
Gly371, Tyr373, Asp382, Arg388 residues and HEM molecule of iNOS
region (C) Binding mode representing the ligand based on atom typeAlso the hydrogen bonding energy which describes the
binding affinity for the docked compounds ranges from
−15.38 kJ mol-1 for CID5315126 to −2.43 for CID5481966
while quercetin have a hydrogen bonding energy of −8.42
kJ mol-1.
The ligand-protein interaction analysis for the top
ten docking hits was calculated using MVD ligand en-
ergy inspector. The ligand–protein interaction includ-
ing the residues present, their interaction distances
and interaction energy and the interacting atoms of
the protein and the ligand is shown in Table 2. The
molecular docking simulation revealed that the top
docking poses were found to be docked into the bind-
ing cavity displaying both bonded and non bonded
interaction.
The top three docking hits showed common molecular
interaction with Asp382, Tyr347 and HEM molecule.
The snapshots of ligand-protein interaction and the bind-
ing mode for the top three docking hits (CID44610309,
CID44259709, CID13964550) and quercetin is shown
in Figure 1A,B,C, Figure 2A,B,C, Figure 3A,B,C and
Figure 4A,B,C.een CID5315126 (green) and Asp282, Trp346, Tyr347,Pro350,
(B) Binding mode of CID5315126 (green) to iNOS active site
and the protein based on amino acid residue type colouring.
Table 3 Lipinski rule of five filter including TPSA for the
top poses
SN Compound ID HBA HBD Mol. Wt. XLog P3 Rot B TPSA
1 5281604 7 4 316.26 1.3 2 116
2 5315126 7 5 370.35 3.5 3 127
3 9818879 7 4 330.29 1.6 4 116
4 5481966 7 5 370.35 4.1 3 127
5 5282154 8 5 332.26 1.5 2 137
6 13964550 6 3 300.26 1.2 2 96.2
7 5281691 7 4 316.26 1.9 2 116
8 11834044 7 4 316.26 2.5 2 116
9 6477685 6 4 312.27 2.0 2 107
10 Quercetin 1 5 302.23 1.5 1 127
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hits and quercetin is shown in Table 3. Lipinski rule of five
is a rule to evaluate drug likeness to determine if a che-
mical compound has a certain pharmacological or bio-
logical activity to make it an orally active drug in humans
(Lipinski 2008; Lipinski et al. 1997). It is observed from
Table 3, the hydrogen bond acceptor (HBA) of quercetin
is very low (only one HBA) compared to HBA of the top
docking hits (6–8 HBA). The high number of HBA of the
analogues could be an important factor and hence the
analogues showed better binding affinity and molecular
interaction with iNOS enzyme compared to quercetin.
Additionally, the top docking hits have lower topological
surface area (TPSA) values than quercetin suggesting that
these compounds might have better oral bioavailability com-
pared to quercetin (the oral bioavailability is inversely pro-
portional to topological polar surface area) (Freitas 2006).ADME-toxicity analysis
The QuikProp (Schrödinger 2012) prediction for the top
docking hits and quercetin is shown in Table 4. FromFigure 3 (A) Predicted bonded interactions (green dashed lines) betw
and HEM molecule of iNOS (B) Binding mode of CID9818879 (green)
ligand based on atom type and the protein based on amino acid resiTable 4, it is revealed that the top docking hits have
MDCK cell permeability (QPPMDCK) in the acceptable
range except for quercetin and CID9818879, the docked
compounds are also in permissible range for IC50 value
for blockage of HERG K+ channels (QPlogHERG),
Caco-2 cell permeability (QPPCaco) and brain/blood
partition coefficient (QPlogBB). More interestingly, the
top docking hits showed higher human oral absorption
(PercentHuman-OralAbsorption) ranging from 58.62%
(CID5282154) to 69.077% (CID5481966) compared with
53.424% of quercetin.
Also, the top docking hits used in the present study
does not violate Lipinski rule of five parameters. Lipinski
rule of five is a rule to evaluate drug likeness to determine
if a chemical compound has a certain pharmacological or
biological activity to make it an orally active drug in
human (Lipinski 2008; Lipinski et al. 1997). However, the
rule does not predict whether a compound is pharmaco-
logically active.
Again from the LD50 mouse and probability of health
effects predictions for the top docking hits and quer-
cetin using ACD/ I-Lab 2.0 (Advanced Chemistry
Development, Inc 1994 ) revealed the top docking hits
have lower LD50 and lesser chance of health effects
(shown in Table 5). The comparative analysis on the
LD50 oral revealed CID11834044, CID13964550,
CID5281604 and CID 6477685 have higher LD50 oral
compared to quercetin (shown in Figure 5). Addition-
ally, the comparative analysis on probability of health
effects showed the top docking hits have more or less
similar behaviour of health effects with quercetin ex-
cept for CID5282154 and CID9818879 which showed
chances of health effect on gastrointestinal system and
lung (shown in Figure 6). In short, the top docked com-
pounds could be lead molecule or a potential anti-
cancer compound with enhanced pharmacological
properties as compared to quercetin.een CID9818879 (green) and Asp382, Tyr347, Pro350 residues
to iNOS active site region (C) Binding mode representing the
due type colouring.
Figure 4 (A) Predicted bonded interactions (green dashed lines) between quercetin (green) and Gln263, Pro350, Gly371 Asp382,
Arg388 residue and HEM molecule of iNOS (B) Binding mode of quercetin (green) to iNOS active site region (C) Binding mode
representing the ligand based on atom type and the protein based on amino acid residue type colouring.
Singh and Konwar SpringerPlus 2012, 1:69 Page 6 of 10
http://www.springerplus.com/content/1/1/69Conclusions
The molecular docking studies with quercetin and its ana-
logues into the binding cavity of iNOS inducible showed
the analogues having more favourable interaction than
quercetin with better rerank score, docking score, hydro-
gen bonding energy and ligand-protein interaction energy
compared to quercetin. As earlier reported in literature,
quercetin is known for having anti-cancer property and
inhibiting the iNOS enzyme, the analogues docked at the
binding cavity could have also possess some sort of anti-
cancer property as it is 95% similar to quercetin retrived
form the NCBI PubChem database. The docked com-
pounds used in the present study do not violate the
Lipinski rule of five parameters.
Also, from the ADME-Toxicity prediction using QikProp
and ACD/ I-Lab 2.0 revealed the docked compounds are
in the acceptable range of various pharmacological para-Table 4 ADME and pharmacological parameters prediction fo
SN CIDa QPPMDCKb QPlogHERGc QPPCacod Rule
1 5281604 46.45 −5.78 112.076 0
2 5315126 39.535 −5.519 96.549 0
3 9818879 15.081 −5.291 39.584 0
4 5481966 44.662 −5.886 108.08 0
5 5282154 33.312 −4.486 82.401 0
6 13964550 41.929 −6.124 101.947 0
7 5281691 63.477 −4.866 149.622 0
8 11834044 43.054 −4.535 104.474 0
9 6477685 45.568 −4.337 110.106 0
10 Quercetin 20.486 −4.032 52.551 0
aCompound I.D’s from NCBI PubChem database.
bPredicted apparent MDCK cell permeability in nm/s (acceptable range: <25 is poor
cPredicted IC50 value for blockage of HERG K
+ channels (concern below −7).
dPredicted Caco-2 cell permeability in nm/s (acceptable range: <25 is poor, <500 is
eNumber of violations of Lipinski’s rule of five (Lipinski et al. 1997; Bracket should b
fPredicted brain/blood partition coefficient (Concern value is–3.0 to – 1.2).
gPredicted human oral absorption on 0 to 100% scale (acceptable range: <25% is p
hPredicted aqueous solubility, (Concern value is −6.5 to – 0.5).meters and they have similar behaviour of health effects
and LD50 compared to quercetin. Interestingly, the top
dockings showed higher human oral absorption ranging
from 58.62% (CID5282154) to 69.077% (CID5481966)
compared with 53.424% of quercetin which is primary
concern of this study as the clinical use of quercetin is li-
mited by its low oral bioavailability.
Therefore we conclude that these compounds could be
a potential lead molecule and supports for experimental
testing against iNOS enzyme as anti cancer compounds.
Methods
Protein preparation
The three-dimensional crystal structure of human indu-
cible nitric oxide synthase (PDB ID: 4NOS) was retrieved
from the Protein Databank Bank (http://www.rcsb.org/).
The coordinates of the dimeric crystallized iNOS isr the top docking hits using QikProp











, >500 is great).
great).
e closed.
oor, >80% is high).
Table 5 LD50 and probability of health effects prediction for the docking hits and quercetin using ACD/ I-Lab 2.0
ADME-Tox parameters 5281604 5315126 9818879 5481966 5282154 13964550 5281691 11834044 6477685 Quercetin
LDa50 mouse (mg kg
−1,
intraperitoneal)
250 340 830 340 130 130 370 200 270 450
LDa50 mouse (mg kg
−1, oral) 1700 570 440 570 650 1500 680 960 2000 670
LDa50 mouse (mg kg
−1, intravenous) 220 190 62 190 71 230 140 110 310 350
LDa50 mouse (mg kg
−1,
subcutaneous)
400 120 48 120 57 250 80 120 390 160
Prob. of blood effectb 0.3 0.85 0.92 0.85 0.9 0.33 0.3 0.78 0.29 0.34
Prob. of cardiovascular system
effectb
0.69 0.47 0.57 0.47 0.79 0.84 0.69 0.69 0.73 0.8
Prob. of gastrointestinal system
effectb
0.68 0.78 1 0.78 1 0.77 0.64 0.64 0.62 0.72
Prob. of kidney effectb 0.77 0.82 0.64 0.82 0.66 0.8 0.77 0.77 0.78 0.79
Prob. of liver effectb 0.35 0.47 0.57 0.47 0.06 0.41 0.35 0.35 0.27 0.3
Prob. of lung effectb 0.37 0.94 0.89 0.94 0.88 0.26 0.37 0.37 0.41 0.38
a- Estimates LD50 value in mg/kg after intraperitoneal, oral, intravenous and subcutaneous administration to mice.
b- Estimates probability of blood, gastrointestinal system, kidney, liver and lung effect at therapeutic dose range.
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(heme), BH4, Zn
+2 atom, ethylisothiourea and has a reso-
lution of 2.25 Å. (Fischmann et al. 1999). For molecular
docking purpose, the dimeric molecule and iron protopor-
phyrin IX (heme) was loaded in the Molego Virtual
Docker (MVD) and all the water molecules were removed.
Chemical similarity search
The 2D structure of quercetin (CID5280343) was retrieved
from the NCBI PubChem database (Bolton et al. 2008;
Wang et al. 2010) and performed a chemical structure
search of quercetin at the NCBI PubChem database to
retrieve the related compound and analogues. The search
parameters were set at 95% similarity subjected to LipinskiFigure 5 Comparative analysis on LD50 mouse (intraperitoneal, oral, int
9818879, 5481966, 5282154, 13964550, 5281691, 11834044, 6477685rule of five filters (Lipinski et al. 1997; Lipinski 2008)
resulting with 85 compounds.
The retrieved compounds were converted to three-
dimensional format using the ChemOffice 2010 (Che-
mOffice 2010: CambridgeSoft Corporation) for docking
purposes. The energy of these compound were opti-
mized using MM2 force field methods (Ulrich and
Norman 1982) and save as sybyl mol2 file format using
ChemOffice 2010.
Computation
Potential ligand binding site for iNOS dimer (PDB ID:
4NOS) was predicted using MVD, having a volume of
678.91 Å3 and a surface area of 1245.44 Å2. The bindingravenous, subcutaneous) for Compound ID (5281604, 5315126,
and quercetin).
Figure 6 Comparative analysis on probability of health effect on blood, cardiovascular system, gastrointestinal system, kidney, liver
and lung for Compound ID (5281604, 5315126, 9818879, 5481966, 5282154, 13964550, 5281691, 11834044, 6477685 and quercetin).
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0.28, Y 99.79, Z 8.70) using MVD.
The 85 analogues retrieved from the NCBI PubChem
database were imported in the Molegro Virtual Docker
(MVD). Bond flexibility of the compounds was set along
and the side chain flexibility of the protein for the active
site residues (Trp372, Glu377, Trp463, Phe476) was set
with a tolerance of 1.10 and strength of 0.90 for docking
simulations. RMSD threshold for multiple cluster poses
was set at 2.00 Å. The docking algorithm was set at a
maximum iteration of 1,500 with a simplex evolution size
of 50 and a minimum of 10 runs were performed for
each compound. The best pose of each compound was
selected for the subsequent ligand–protein interaction
energy analysis.
Molecular docking was carried out using Molegro
Virtual Docker. MVD is based on a differential evolution
algorithm; the solution of the algorithm considers the sum
of the intermolecular interaction energy between the
ligand and the protein and the intramolecular interaction
energy of the ligand. The docking energy scoring function
is based on the modified piecewise linear potential (PLP)
with new hydrogen bonding and electrostatic terms
included. Full description of the algorithm and its reliabi-
lity compared to other common docking algorithm is
described by Thomsen et al. (Thomsen and Christensen
2006).
ADME-toxicity prediction
ADME-Toxicity for the top docking hits and quercetin
was predicted using QikProp (Schrödinger 2012). Qik-
Prop predicts physically significant descriptors and
pharmaceutically relevant properties of organic mole-
cules, either individually or in batches. QikProp provides
ranges for comparing a particular molecule’s propertieswith those of 95% of known drugs. In the present study
QikProp properties and descriptors such as apparent
MDCK cell permeability (QPPMDCK), IC50 value for
blockage of HERG K+ (QPlogHERG), Caco-2 cell perme-
ability (QPPCaco), Lipinski rule of five (Lipinski et al. 1997;
Lipinski 2008), brain/blood partition coefficient (QPlogBB),
human oral absorption on 0 to 100% scale (Percent Huma-
nOralAbsorption), aqueous solubility (QPlogS) for the top
docking hits and quercetin was predicted to obtain the
ADME properties of the compounds.
Additionally LD50 mouse and probability of health effects
predictions for the top docking hits were calculated using
ACD/ I-Lab 2.0 (Advanced Chemistry Development, Inc
1994 ) which is a web-based service that provides instant
access to spectral and chemical databases, and predicts
properties including physicochemical, ADME, toxicity
characteristics. Also a comparative analysis were performed
for LD50 mouse (intraperitoneal, oral, intravenous, subcuta-
neous) and probability of health effect of blood, cardiovas-
cular system, gastrointestinal system, kidney, liver and lung
for the top docking hits.
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